The effects of direct factor Xa Inhibitor (Rivaroxaban) on the human osteoblastic cell line SaOS2

Connective Tissue Research

Volumn 53, Issue 6, 2012, Pages 446-450

  Gigi, Roy ^a   Salai, Moshe ^a   Dolkart, Oleg ^a   Chechik, Ofir ^a   Katzburg, Sarah ^a   Stern, Naftali ^a   Somjen, Dalia ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

cell proliferation; energy metabolism; mineralization; rivaroxaban; SaOS2; thromboprophylaxis

Indexed keywords

ALKALINE PHOSPHATASE; BLOOD CLOTTING FACTOR 10A; CREATINE KINASE; RIVAROXABAN;

ARTICLE; BONE MINERALIZATION; CELL CULTURE; CELL GROWTH; CELL STRAIN SAOS2; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG EFFECT; ENERGY METABOLISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; OSSIFICATION; OSTEOBLAST;

ALKALINE PHOSPHATASE; ANTICOAGULANTS; CALCIFICATION, PHYSIOLOGIC; CELL LINE; CREATINE KINASE; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FEMALE; HUMANS; MORPHOLINES; OSTEOBLASTS; THIOPHENES;

EID: 84869810110     PISSN: 03008207     EISSN: 16078438     Source Type: Journal    
DOI: 10.3109/03008207.2012.711867     Document Type: Article

References (39)

1. Bergqvist, D., and Lindblad, B. (1994). Incidence of venous thromboembolism in medical and surgical patients. In Prevention of Venous Thromboembolism, Bergqvist D., Comerota A.J., Nicolaides A.N., and Scurr J.H. (eds.) pp. 3-15. London: Med-Orion
2. Fitts, W.T., Lehr, H.B., Bitner, R.L., and Spelman, W.J. (1964). An analysis of 950 fatal injuries. Surgery 56:663-668.
3. Geerts, W.H., Code, K.I., Jay, R.M., Chen, E., and Szalai, J.P. (1994). A prospective study of venous thromboembolism after major trauma. N. Engl. J. Med. 331:1601-1606.
4. Knudson, M.M., Collins, J.A., and Goodman, S.B. (1992). Thromboembolism following multiple trauma. J. Trauma 32:1-11.
5. Montgomery, K.D., Geerts, M.D., Potter, H.F., and Helfet, D.L. (1996). Thromboembolic complications in patients with pelvic trauma. Clin. Orthop. 329:68-87.
6. O'Malley, K.F., and Ross, S.E. (1990). Pulmonary embolism in major trauma patients. J. Trauma 30:748-750.
7. Sevitt, S., and Gallagher, N.G. (1961). Venous thrombosis and pulmonary embolism:A clinico-pathological study in injured and burn patients. Br. J. Surg. 48:475-489.
8. Shackford, S.R., Davis, J.W., Hollingsworth-Fridlund, P., Brewer, N.S., Hoyt, D.B., and Mackersie, R.C. (1990). Venous thromboembolism in major trauma. Am. J. Surg. 159:365-369.
9. Kearon, C. (2003). Duration of venous thromboembolism prophylaxis after surgery. Chest 124(Suppl.):386S-392S.
10. Colwell Jr., C.W., and Spiro, T.E. (1995). Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. Clin. Orthop. 319:215-222.
11. Francis, C.W., Pellegrini Jr., V.D., Totterman, S., Boyd Jr., A.D., Marder, V.J., Liebert, K.M., Stulberg, B.N., Ayers, D.C., Rosenberg, A., Kessler, C., and Johanson, N.A. (1997). Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J. Bone Joint Surg. Am. 79:1365-1372.
12. Moskovitz, P.A., Ellenberg, S.S., Feffer, H.L., Kenmore, P.I., Neviaser, R.J., Rubin, B.E., and Varma, V.M. (1978). Low dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. J. Bone Joint Surg. Am. 60:1065-1070.
13. Matzsch, T., Bergqvist, D., Hedner, U., Nilsson, B., and Ostergaard, P. (1990). Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb. Haemost. 63:505-509.
14. Muir, J.M., Andrew, M., Hirsch, J., Weitz, J.I., Young, E., Deschamps, P., and Shaughnessy, S.G. (1997). A histomorphometric comparison of the effects of heparin and low molecular weight heparin on cancellous bone in rats. Blood 89:3236-3242.
15. Chowdhury, M.H., Hamada, C., and Dempster, D.W. (1992). Effects of heparin on osteoclast activity. J. Bone Miner. Res. 7: 771-777.
16. Kock, H.J., and Handschin, A.E. (2002). Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: An invitro investigation. Clin. Appl. Thromb. Hemost. 8:251-255.
17. Perzborn, E., Strassburger, J., Wilmen, A., Pohlmann, J., Roehrig, S., Schlemmer, K.H., and Straub, A. (2005). In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - An oral, direct Factor Xa inhibitor. J. Thromb. Haemost. 3:514-521.
18. Kubitza, D., Becka, M., Wensing, G., Voith, B., and Zuehlsdorf, M. (2005). Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. 78:412-421.
19. Eriksson, B.I., Quinlan, D.J., and Weitz, J.I. (2009). Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin. Pharmacokinet. 48: 1-22.
20. Akkas, N., Yeni, Y.N., Turan, B., Delilbasi, E., and Gunel, U. (1997). Effect of medication on biomechanical properties of rabbit bones: Heparin-induced osteoporosis. Clin. Rheumatol. 16:585-595.
21. Barbour, L.A., Kick, S.D., Steiner, J.F., LoVerde, M.E., Heddleston, L.N., Lear, J.L., Barón, A.E., and Barton, P.L. (1994). A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am. J. Obstet. Gynecol. 170:862-869.
22. Bhandari, M., Hirsh, J., Weitz, J.I., Young, E., Venner, T.J., and Shaughnessy, S.G. (1998). The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb. Haemost. 80:413-417.
23. Mazanec, D.J., and Grisanti, J.M. (1989). Drug-induced osteoporosis. Cleve Clin. J. Med. 56:297-303.
24. Muir, J.M., Andrew, M., Hirsh, J., Weitz, J.I., Young, E., Deschamps, P., and Shaughnessy, S.G. (1996). Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 88: 1314-1320.
25. Deo, S., Gibbons, C.L., Emerton, M., and Simpson, A.H. (1995). Total hip replacement in renal transplant patients. J. Bone Joint Surg. Br. 77:299-302.
26. Devlin, V.J., Einhorn, T.A., Gordon, S.L., Alvarez, E.V., and Butt, K.M. (1988). Total hip arthroplasty after renal transplantation. Long-term follow-up study and assessment of metabolic bone status. J. Arthroplasty 3:205-213.
27. Kobayashi, S., Eftekhar, N.S., and Terayama, K. (1994). Predisposing factors in fixation failure of femoral prostheses following primary Charnley low friction arthroplasty. A 10- to 20-year followup study. Clin. Orthop. Relat Res. 306:73-83.
28. Stinchfield, F., Sankaran, B., and Samilson, R. (1955). The effect of anticoagulant therapy on bone repair. J. Bone Joint Surg. Am. 28:270-282.
29. Somjen, D., Katzburg, S., Grafi-Cohen, M., Knoll, E., Sharon, O., and Posner, G.H. (2011). Vitamin D metabolites and analogs induce lipoxygenasemRNAexpression and activity as well as reactive oxygen species (ROS) production in human bone cell line. J. Steroid Biochem. Mol. Biol. 123:85-89.
30. Somjen, D., Kohen, F., Lieberherr, M., Gayer, B., Schejter, E., Katzburg, S., Limor, R., Sharon, O., Knoll, E., Posner, G.H., Kaye, A.M., and Stern, N. (2005). Membranal effects of phytoestrogens and carboxy derivatives of phytoestrogens on human vascular and bone cells: New insights based on studies with carboxybiochanin A. J. Steroid Biochem. Mol. Biol. 93:293-303.
31. Katzburg, S., Lieberherr, M., Ornoy, A., Klein, B.Y., Hendel, D., and Somjen, D. (1999). Isolation and hormonal responsiveness of primary cultures of human bone-derived cells: Gender and age differences. Bone 25:667-673.
32. Solayar, G.N., Walsh, P.M., and Mulhall, K.J. (2011). The effect of a new direct factor Xa inhibitor on human osteoblasts: An in-vitro study comparing the effect of rivaroxaban with enoxaparin. BMC Musculoskelet. Disord. 12:247-254.
33. Aubin, J.E. (1998). Advances in the osteoblast lineage. Biochem. Cell Biol. 76:899-910.
34. Malavalk, L., Liu, F., Roche, P., and Aubin, J.E. (1999). Kinetics of osteoprogenitor proliferation and osteoblast differentiation in vitro. J. Cell. Biochem. 7:616-627.
35. Kock, H.J., Werther, S., Uhlenkott, H., and Taeger, G. (2002). Influence of unfractionated and low-molecular-weight heparin on bone healing: An animal model. Unfallchirurg 105:791-796.
36. Hausser, H.J., and Brenner, R.E. (2004). Low doses and high doses of heparin have different effects on osteoblast-like saos-2 cells in vitro. J. Cell. Biochem. 91:1062-1073.
37. Matziolis, G., Perka, C., Disch, A., and Zippel, H. (2003). Effect of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif. Tissue Int. 73: 370-379.
38. Canalis, E., McCarthy, T., and Centrella, M. (1988). Isolation and characterization of insulin-like growth factor I (somatomedin-C) from cultures of fetal rat calvariae. Endocrinology 122:22-27.
39. Andress, D.L. (1995). Heparin modulates the binding of insulin-like growth factor (IGF) binding protein-5 to a membrane protein in osteoblastic cells. J. Biol. Chem. 270:28289-28296.